Intersect ENT, Inc. (XENT) |
| 28.24 0 (0%) 04-24 15:47 |
| Open: | 28.25 |
| High: | 28.25 |
| Low: | 28.23 |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | -10.54 |
| Exchange: | NASDAQ Global Market |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 5.07 |
| Resistance 1: | 4.47 |
| Pivot price: | 4.13 |
| Support 1: | 3.50 |
| Support 2: | 2.91 |
| 52w High: | 28.25 |
| 52w Low: | 15.92 |
Intersect ENT, Inc. is a medical technology firm focused on ear, nose, and throat (ENT) solutions, operating within the United States. Its product portfolio includes: PROPEL, PROPEL Mini, and PROPEL Contour: These are steroid-eluting implants. PROPEL is designed to maintain the patency of surgically enlarged sinuses, while PROPEL Mini targets patients undergoing frontal sinus procedures. PROPEL Contour specifically addresses the frontal and maxillary sinus ostia, or passages, within the dependent sinuses. SINUVA: Another steroid-releasing implant, intended for patient care in a clinical office environment. VENSURE Navigable and Stand-alone balloon: A sterile, single-use balloon device that facilitates access to and treatment of the frontal, sphenoid, and maxillary ostia in adult patients via a trans-nasal method. CUBE Navigation System: A digital guidance system offering high-accuracy navigation for ENT and associated skull-base surgical interventions. The company, originally established as Sinexus, Inc. in 2003, rebranded to Intersect ENT, Inc. in November 2009. Its corporate headquarters are located in Menlo Park, California.
| EPS | -1.390 |
| Book Value | 15.430 |
| PEG Ratio | 2.58 |
| Gross Profit | 3.832 |
| Profit Margin (%) | -14.51 |
| Operating Margin (%) | -4.67 |
| Return on Assets (ttm) | 0.4 |
| Return on Equity (ttm) | -8.9 |
Wed, 24 Dec 2025
Google drops $4.75bn on data center and energy firm Intersect - IT Pro
Fri, 13 May 2022
Medtronic completes Intersect ENT acquisition - Drug Delivery Business
Fri, 06 Aug 2021
Medtronic to Acquire Intersect ENT - Aug 6, 2021 - Medtronic
Thu, 19 Apr 2018
Regaining a Sense of Smell - TMC Houston
Mon, 02 Apr 2018
Intersect ENT launches Sinuva steroid-releasing sinus implant - MassDevice
Wed, 01 Mar 2017
Intersect ENT Announces FDA Approval Of PROPEL Contour, For Use In Treating The Frontal And Maxillary Sinuses - Medical Design & Outsourcing
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |